Theravance Biopharma to Participate in an Upcoming Investor Conference
Theravance Biopharma (NASDAQ: TBPH) will present at the SVB Leerink 11th Annual Global Healthcare Conference on February 16, 2022, at 3:40 pm ET. A webcast of the event is available on Theravance.com and will be archived for 30 days.
Theravance Biopharma focuses on developing respiratory medicines, with its flagship product being YUPELRI®, an FDA-approved inhalation solution for chronic obstructive pulmonary disease (COPD). The company is also associated with potential payments from Glaxo Group Limited through agreements with Innoviva, Inc..
- None.
- None.
DUBLIN, Feb. 2, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will present at the SVB Leerink 11th Annual Global Healthcare Conference on Wednesday, February 16, at 3:40 pm ET (12:40 pm PT/8:40 pm GMT).
A webcast of the event may be accessed by visiting Theravance.com, under the Investors section, Presentations and Events. Replay of the webcast will be archived on the Company's website for 30 days.
About Theravance Biopharma
Theravance Biopharma, Inc. is a biopharmaceutical company primarily focused on the discovery, development and commercialization of respiratory medicines. Its core purpose is to create medicines that help improve the lives of patients suffering from respiratory illness.
In pursuit of its purpose, Theravance Biopharma leverages decades of respiratory expertise to discover and develop transformational medicines that make a difference. These efforts have led to the development of FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its respiratory pipeline of internally discovered programs is targeted to address significant patient respiratory needs.
Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY.
For more information, please visit www.theravance.com.
THERAVANCE BIOPHARMA®, THERAVANCE®, and the Cross/Star logo are registered trademarks of the Theravance Biopharma group of companies (in the US and certain other countries).
YUPELRI® is a registered trademark of Mylan Specialty L.P., a Viatris Company. Trademarks, trade names or service marks of other companies appearing on this press release are the property of their respective owners.
Contact Information:
Contact: Gail B. Cohen
Corporate Communications / 917-214-6603
View original content to download multimedia:https://www.prnewswire.com/news-releases/theravance-biopharma-to-participate-in-an-upcoming-investor-conference-301473447.html
SOURCE Theravance Biopharma, Inc.
FAQ
When will Theravance Biopharma present at the SVB Leerink Healthcare Conference?
How can I access the Theravance Biopharma conference webcast?
What is YUPELRI® by Theravance Biopharma?
What is the stock symbol for Theravance Biopharma?
What kind of medicines does Theravance Biopharma develop?
